These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16204896)

  • 21. Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activation.
    Zivelin A; Ogawa T; Bulvik S; Landau M; Toomey JR; Lane J; Seligsohn U; Gailani D
    J Thromb Haemost; 2004 Oct; 2(10):1782-9. PubMed ID: 15456490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystal structures of human factor Xa complexed with potent inhibitors.
    Maignan S; Guilloteau JP; Pouzieux S; Choi-Sledeski YM; Becker MR; Klein SI; Ewing WR; Pauls HW; Spada AP; Mikol V
    J Med Chem; 2000 Aug; 43(17):3226-32. PubMed ID: 10966741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macromolecular substrate-binding exosites on both the heavy and light chains of factor XIa mediate the formation of the Michaelis complex required for factor IX-activation.
    Sinha D; Marcinkiewicz M; Navaneetham D; Walsh PN
    Biochemistry; 2007 Aug; 46(34):9830-9. PubMed ID: 17676929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptor rigidity and ligand mobility in trypsin-ligand complexes.
    Guvench O; Price DJ; Brooks CL
    Proteins; 2005 Feb; 58(2):407-17. PubMed ID: 15578663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding protein-ligand interactions: the price of protein flexibility.
    Rauh D; Klebe G; Stubbs MT
    J Mol Biol; 2004 Jan; 335(5):1325-41. PubMed ID: 14729347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of factor XIa (FXIa) catalytic domain exosite residues in substrate catalysis and inhibition by the Kunitz protease inhibitor domain of protease nexin 2.
    Su YC; Miller TN; Navaneetham D; Schoonmaker RT; Sinha D; Walsh PN
    J Biol Chem; 2011 Sep; 286(36):31904-14. PubMed ID: 21778227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A sequential mechanism for exosite-mediated factor IX activation by factor XIa.
    Geng Y; Verhamme IM; Messer A; Sun MF; Smith SB; Bajaj SP; Gailani D
    J Biol Chem; 2012 Nov; 287(45):38200-9. PubMed ID: 22961984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity.
    Chen W; Carvalho LP; Chan MY; Kini RM; Kang TS
    J Thromb Haemost; 2015 Feb; 13(2):248-61. PubMed ID: 25418421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of cAMP-dependent protein kinase complexed with the peptide inhibitor PKI(5-24) and adenosine.
    Narayana N; Cox S; Shaltiel S; Taylor SS; Xuong N
    Biochemistry; 1997 Apr; 36(15):4438-48. PubMed ID: 9109651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative molecular modeling analysis of-5-amidinoindole and benzamidine binding to thrombin and trypsin: specific H-bond formation contributes to high 5-amidinoindole potency and selectivity for thrombin and factor Xa.
    Zhou Y; Johnson ME
    J Mol Recognit; 1999; 12(4):235-41. PubMed ID: 10440994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
    Zeslawska E; Schweinitz A; Karcher A; Sondermann P; Sperl S; Stürzebecher J; Jacob U
    J Mol Biol; 2000 Aug; 301(2):465-75. PubMed ID: 10926521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent.
    Ely LK; Lolicato M; David T; Lowe K; Kim YC; Samuel D; Bessette P; Garcia JL; Mikita T; Minor DL; Coughlin SR
    Structure; 2018 Feb; 26(2):187-198.e4. PubMed ID: 29336885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.
    Corte JR; Fang T; Osuna H; Pinto DJ; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Decicco CP; Wexler RR; Quan ML
    J Med Chem; 2017 Feb; 60(3):1060-1075. PubMed ID: 28085275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).
    Pinto DJP; Orwat MJ; Smith LM; Quan ML; Lam PYS; Rossi KA; Apedo A; Bozarth JM; Wu Y; Zheng JJ; Xin B; Toussaint N; Stetsko P; Gudmundsson O; Maxwell B; Crain EJ; Wong PC; Lou Z; Harper TW; Chacko SA; Myers JE; Sheriff S; Zhang H; Hou X; Mathur A; Seiffert DA; Wexler RR; Luettgen JM; Ewing WR
    J Med Chem; 2017 Dec; 60(23):9703-9723. PubMed ID: 29077405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein.
    Tang J; Yu CL; Williams SR; Springman E; Jeffery D; Sprengeler PA; Estevez A; Sampang J; Shrader W; Spencer J; Young W; McGrath M; Katz BA
    J Biol Chem; 2005 Dec; 280(49):41077-89. PubMed ID: 16199530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Domain V of beta2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318.
    Shi T; Giannakopoulos B; Iverson GM; Cockerill KA; Linnik MD; Krilis SA
    J Biol Chem; 2005 Jan; 280(2):907-12. PubMed ID: 15522884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineering the substrate specificity of xylose isomerase.
    Karimäki J; Parkkinen T; Santa H; Pastinen O; Leisola M; Rouvinen J; Turunen O
    Protein Eng Des Sel; 2004 Dec; 17(12):861-9. PubMed ID: 15713782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.
    Lazarova TI; Jin L; Rynkiewicz M; Gorga JC; Bibbins F; Meyers HV; Babine R; Strickler J
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5022-7. PubMed ID: 16876411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystal structures of thymidylate synthase mutant R166Q: structural basis for the nearly complete loss of catalytic activity.
    Sotelo-Mundo RR; Changchien L; Maley F; Montfort WR
    J Biochem Mol Toxicol; 2006; 20(2):88-92. PubMed ID: 16615077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural analysis of Sindbis virus capsid mutants involving assembly and catalysis.
    Choi HK; Lee S; Zhang YP; McKinney BR; Wengler G; Rossmann MG; Kuhn RJ
    J Mol Biol; 1996 Sep; 262(2):151-67. PubMed ID: 8831786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.